RALEIGH, N.C., Sept. 15, 2011 (GLOBE NEWSWIRE) -- DARA BioSciences, Inc. (Nasdaq:DARA) announced today that the Company has been selected to present the positive clinical data results for KRN5500, its lead compound for Neuropathic Pain, at the 5th Annual Therapeutics Summit to be held September 20-21, 2011 in San Francisco. Linda Jett, MSN, Clinical Director, Drug Development at DARA, will present a poster entitled, "Management of Placebo Response Yields Proof of Concept in Randomized Trial of KRN5500 in Patient with Neuropathic Pain and Cancer."
